7. AbbVie Inc. (NYSE:ABBV)
AbbVie Inc. (NYSE: ABBV) takes the seventh position as the pharmaceutical giant continues answering one of the biggest questions that has followed the company for years: What happens after Humira?
Humira became one of the most commercially successful medicines in pharmaceutical history, treating inflammatory conditions ranging from rheumatoid arthritis to Crohn’s disease. That success also created a problem. When a company becomes heavily dependent on one blockbuster product, the eventual loss of exclusivity can create enormous pressure as biosimilar and generic competition enters the market.
AbbVie Inc. (NYSE: ABBV) knew that challenge was coming, and the company’s response has centered heavily on Skyrizi and Rinvoq.
Those two medicines have emerged as the pillars of the company’s post-Humira growth strategy. Both target chronic inflammatory diseases, allowing AbbVie Inc. (NYSE: ABBV) to maintain its expertise and commercial strength in immunology while transitioning away from its former blockbuster.
CFRA analyst Sel Hardy expects AbbVie Inc. (NYSE: ABBV) to generate compound annual revenue growth in the high-single-digit percentage range through 2029 despite Humira’s loss of exclusivity and Medicare-related headwinds. Even more striking is the projected scale of Skyrizi and Rinvoq. Hardy estimates the two drugs could generate a combined $31 billion in sales in 2027.
That figure explains why Wall Street’s attention has gradually shifted away from asking whether AbbVie Inc. (NYSE: ABBV) can survive Humira’s decline and toward evaluating how large its next generation of medicines can become.
The company is also using acquisitions to strengthen its future pipeline. The acquisition of Apogee Therapeutics is expected to enhance AbbVie Inc. (NYSE: ABBV)’s immunology portfolio, potentially providing additional assets capable of supporting growth as the pharmaceutical landscape evolves.
This acquisition strategy is important because major pharmaceutical companies rarely rely exclusively on internal research. Buying promising biotechnology assets can allow established drugmakers to replenish pipelines and enter new treatment categories faster, although acquisitions always carry execution and clinical-development risks.
CFRA maintains a “buy” rating and a $270 price target for AbbVie Inc. (NYSE: ABBV), compared with a July 30 closing price of $257.41. That translates to only around 5% implied upside based on those figures, which limits its placement in a ranking emphasizing valuation and analyst upside.
However, the headline percentage does not capture the entire story. AbbVie Inc. (NYSE: ABBV) is demonstrating that a pharmaceutical company can move beyond the patent cliff of a historically dominant drug if it successfully builds replacement franchises.
For investors searching for pharmaceutical stocks to buy, dividend healthcare stocks and companies with established immunology franchises, AbbVie Inc. (NYSE: ABBV) remains an important name to watch in 2026.
